Therefore, the present work concluded that compound 20 is the potential lead compounds that can be further manipulated at points 1 and 4 of the 2-pyrrolidinone moiety for the discovery and development of more selective and potent inhibitors of MAGL for neuropathic pain and CNS disorders including cancers. This evidence concerns the gene MGLL and cancer.